Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) and Ardelyx (NASDAQ:ARDX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.
Valuation & Earnings
This table compares Enlivex Therapeutics and Ardelyx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enlivex Therapeutics | N/A | N/A | $1.24 billion | ($0.55) | -1.13 |
| Ardelyx | $427.68 million | 3.68 | -$61.60 million | ($0.23) | -27.70 |
Volatility & Risk
Enlivex Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Profitability
This table compares Enlivex Therapeutics and Ardelyx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enlivex Therapeutics | N/A | 248.08% | 206.39% |
| Ardelyx | -13.58% | -38.11% | -11.85% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Enlivex Therapeutics and Ardelyx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enlivex Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Ardelyx | 1 | 0 | 9 | 1 | 2.91 |
Enlivex Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 2,548.48%. Ardelyx has a consensus price target of $15.73, indicating a potential upside of 146.90%. Given Enlivex Therapeutics’ higher possible upside, equities analysts clearly believe Enlivex Therapeutics is more favorable than Ardelyx.
Insider & Institutional Ownership
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Enlivex Therapeutics beats Ardelyx on 8 of the 14 factors compared between the two stocks.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
About Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
